Intranasal Drug Delivery Market Size, Share, Industry, Forecast and outlook (2024-2031)

Intranasal Drug Delivery Market is segmented By Type (Nasal Spray, Nasal Drops, Nasal Gel, Nasal Powder), By Container Type (Pressurized Container, Non-pressurized Container), By Application (Allergic and Non-allergic Rhinitis, Nasal Congestion, Sinusitis, Asthma, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

Global Intranasal Drug Delivery Market reached US$ 11.2 billion in 2023 and is expected to reach US$ 20.7  billion by 2031, growing at a CAGR of 8.0% during the forecast period 2024-2031.

Intranasal drug delivery is a method of administering medications through the nasal cavity. This route leverages the rich vascularization of the nasal mucosa, allowing drugs to be absorbed directly into the bloodstream, bypassing the gastrointestinal tract and first-pass metabolism in the liver. 

It offers a non-invasive and convenient alternative for delivering various medications, including systemic drugs, vaccines, and treatments for local conditions like nasal congestion and allergies. The rapid absorption and onset of action make intranasal drug delivery particularly useful for conditions that require quick relief, such as migraines and pain.

Market Scope

For more details on this report – Request for Sample

Market Dynamics: Drivers & Restraints

Increasing preference for non-invasive drug administration methods

The global intranasal drug delivery market is driven by the growing preference for non-invasive methods, offering quick onset of action and convenience. This method is particularly beneficial for drugs requiring rapid absorption, such as in emergency settings or treating central nervous system disorders. The convenience and improved patient compliance of intranasal delivery are also boosting its adoption, especially among populations with difficulty with oral or injectable forms, such as pediatric and geriatric patients.

For instance, in July 2024, researchers at the University of Texas Medical Branch recently discovered a significant advancement in the fight against neurodegenerative diseases such as Alzheimer’s disease and dementia. The study, published in Science Translational Medicine, introduces an innovative nasal spray treatment that has shown promising results in clearing harmful tau protein build-up and improving cognitive functions in aged mice models with neurodegenerative diseases.  

Limited absorption

The global intranasal drug delivery market faces challenges due to local irritation and limited absorption through the nasal mucosa. Certain drugs can cause discomfort and inconsistent absorption due to nasal anatomy and mucociliary clearance rates. These challenges limit the effectiveness and acceptance of intranasal drug delivery for medications requiring precise dosing and consistent absorption.

Market Segment Analysis

The global intranasal drug delivery market is segmented based on type, container type, application,  distribution channel, and region.

The nasal spray from the type segment accounted for approximately 43.3% of the intranasal drug delivery  market share

The nasal spray from the type segment accounted for approximately 43.3%. Nasal sprays are a popular method for administering various medications in the intranasal drug delivery market. They deliver a fine mist of medication directly into the nasal cavity, allowing rapid absorption into the bloodstream. This is particularly useful for quick-onset drugs like migraines, nasal congestion, and allergic rhinitis, as well as emergencies like opioid overdose. Nasal sprays are non-invasive and easy to use, making them a preferred alternative to injections or oral medications.

For instance, in October 2023, Otrivin Nasal Mist, a new generation of nasal spray, was launched to bring greater comfort and ease of use to people suffering from nasal congestion due to colds, allergic rhinitis, and sinusitis. The innovation, developed by consumer health company Haleon and Aptar Pharma, uses new microdroplet technology to dispense a full but gentle mist that evenly covers inflamed areas, with no dripping at the back of the nose and throat.

Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to increased awareness and improved healthcare facilities. Government initiatives and favorable reimbursement policies are also contributing to this growth. Asia is expected to experience high growth, with China and India dominating due to large investments, a rising population, and government funding. 

For instance, in April 2024, Amneal Pharmaceuticals announced the availability of its Over-the-Counter Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, following FDA approval. This generic equivalent is manufactured in the U.S. and is used to treat drug overdose from opioids like heroin, fentanyl, and prescription opioid medications. The FDA has approved the medication.

Market Segmentation

By Type

• Nasal Spray
• Nasal Drops
• Nasal Gel
• Nasal Powder

By Container Type

• Pressurized Container
• Non-pressurized Container

By Application

• Allergic and Non-allergic Rhinitis
• Nasal Congestion
• Sinusitis
• Asthma
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies 

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Market Competitive Landscape

The major global players in the market include AstraZeneca, Baxter International, Inc., Becton, Dickinson, and Company, GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, Pfizer Inc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc, Aegis Therapeutics LLC among others.

Key Developments

• In November 2023, Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, just announced an expansion of its nasal drug delivery capabilities by adding a family of innovative nasal powder delivery devices developed in partnership with IDC. Intranasal drug delivery is a good alternative to conventional delivery routes for both local and systemic drug delivery due to its simplicity, safety, and faster onset of action. 

Why Purchase the Report?

• To visualize the global intranasal drug delivery market segmentation based on type, container type, application, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of the intranasal drug delivery market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global intranasal drug delivery market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies